Analyses of CD20 Monoclonal Antibody–Mediated Tumor Cell Killing Mechanisms: Rational Design of Dosing Strategies

Since approval of rituximab for treatment of B cell non-Hodgkin lymphoma, development of monoclonal antibodies (mAbs) for cancer treatment and elucidation of their cytotoxic mechanisms have been subject to intense investigations. Compelling evidence indicates that rituximab and another CD20 mAb, ofa...

Full description

Saved in:
Bibliographic Details
Main Authors: Taylor, Ronald P., Lindorfer, Margaret A.
Format: Artigo
Language:Inglês
Published: The American Society for Pharmacology and Experimental Therapeutics 2014
Subjects:
Minireview—Special Section on Highlights from IUPHAR
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC4201137/
https://ncbi.nlm.nih.gov/pubmed/24944188
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/mol.114.092684
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items